logo
Share SHARE
FONT-SIZE Plus   Neg

Aeterna Zentaris' Phase3 Perifosine Trial Fails To Meet Primary Endpoint

Late-stage oncology drug development company Aeterna Zentaris Inc. (AEZS, AEZ.TO) said its Phase 3 trial evaluating perifosine in refractory advanced colorectal cancer patients failed to meet primary endpoint. Trading for Aeterna halted in early morning hours and shares are currently down more than 55 percent on the Nasdaq.

The focus of the X-PECT study was improvement of overall survival with perifosine in comparison with capecitabine + placebo. The trial involved 468 patients in 65 sites in the U.S and the study was conducted by the Company's North American licensee partner, Keryx Biopharmaceuticals, Inc. (KERX).

Aeterna Zentaris said it is very disappointed that the trial result. The company will continue further data analyses in collaboration with our licensee partners, in order to determine the future development strategy for perifosine.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Ford Motor Co. has issued a safety recall for nearly 117,000 vehicles in North America to replace improperly tempered bolts in seats and seatbelts that could fracture. The affected vehicles include 2014 Ford F-150 pickup trucks, 2014 E-Series vans, 2014-15 Ford Escape SUVs and 2015 Lincoln MKC SUVs to replace improperly tempered bolts in seats and seatbelts. Electronics retailer Best Buy is adding Dyson mini-shops to its select stores in the U.S. next month. Dyson is a maker of vacuums, hair dryers, air purifiers and other household items. Starting in August, about 90 U.S. Best Buy stores will get new Dyson Demo Experiences - dedicated spaces that will enable customers try out Dyson products as if they were in their own home. Shares of Airbus Group SE were losing around 4 percent in the morning trading in Paris after the aerospace and defense major reported Thursday a sharp decline in its second-quarter profit with lower revenues. Further, the company maintained its guidance for the full year 2017.
comments powered by Disqus
Follow RTT